Felix M Arellano

Summary

Publications

  1. ncbi Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile
    Felix M Arellano
    Risk Management Resources, LLC Bridgewater, NJ 08807, USA
    Pharmacoepidemiol Drug Saf 15:861-72. 2006
  2. ncbi Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis
    Felix M Arellano
    Risk Management Resources, 726 Route 202 South, Suite 320 361, Bridgewater, New Jersey, USA
    J Invest Dermatol 127:808-16. 2007
  3. ncbi Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom
    Felix M Arellano
    Risk MR, LLC, Bridgewater, NJ, USA
    J Allergy Clin Immunol 123:1111-6, 116.e1-13. 2009
  4. ncbi The withdrawal of rofecoxib
    Felix M Arellano
    Risk Management Resources, Califon, NJ 07830, USA
    Pharmacoepidemiol Drug Saf 14:213-7. 2005
  5. ncbi Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States
    Felix M Arellano
    Risk MR, LLC, Bridgewater, NJ, USA
    Pediatr Allergy Immunol 22:469-76. 2011

Detail Information

Publications5

  1. ncbi Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile
    Felix M Arellano
    Risk Management Resources, LLC Bridgewater, NJ 08807, USA
    Pharmacoepidemiol Drug Saf 15:861-72. 2006
    ..COX-2 and NSAIDS differ in their gastrointestinal (GI) and cardiovascular (CV) toxicity from pharmacological, clinical and epidemiologic point of views...
  2. ncbi Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis
    Felix M Arellano
    Risk Management Resources, 726 Route 202 South, Suite 320 361, Bridgewater, New Jersey, USA
    J Invest Dermatol 127:808-16. 2007
    ..It is difficult to disentangle the effects of severity of disease on outcome versus the true effects of drugs. However, in the adjusted analysis, severity of AD was the main factor associated with an increased risk of lymphoma...
  3. ncbi Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom
    Felix M Arellano
    Risk MR, LLC, Bridgewater, NJ, USA
    J Allergy Clin Immunol 123:1111-6, 116.e1-13. 2009
    ..Atopic dermatitis (AD) has been associated with an increased risk of lymphoma...
  4. ncbi The withdrawal of rofecoxib
    Felix M Arellano
    Risk Management Resources, Califon, NJ 07830, USA
    Pharmacoepidemiol Drug Saf 14:213-7. 2005
  5. ncbi Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States
    Felix M Arellano
    Risk MR, LLC, Bridgewater, NJ, USA
    Pediatr Allergy Immunol 22:469-76. 2011
    ..In conclusion, a considerable proportion of children and adolescents with asthma do not receive any asthma medication. Among those who do receive medication, adherence to current guidelines is questionable...